Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on April 14, 2005, detailing two key events that occurred on April 8, 2005. The company's board of directors approved an additional annual retainer of $5,000 for the Chairman of the Audit Committee, Mr. George L. Sing. This supplemental payment is on top of the standard $15,000 annual retainer provided to all non-employee directors, recognizing the specific responsibilities of the Audit Committee Chair. Furthermore, the board approved an amendment to the Company's Code of Business Conduct and Ethics. This amendment strengthens the company's ethical guidelines by explicitly adding sections on the protection of company assets and a clear prohibition against insider trading based on material non-public information. These updates reflect a commitment to robust corporate governance and ethical business practices.
Key Highlights
- 1Additional $5,000 annual retainer approved for the Chairman of the Audit Committee.
- 2Total annual retainer for the Audit Committee Chairman is now $20,000 ($15,000 regular + $5,000 additional).
- 3The amendment to the Code of Business Conduct and Ethics adds a section on protecting company assets.
- 4A new section prohibits officers, directors, and employees from trading securities based on material non-public information.
- 5The amended Code applies to all directors, officers, and employees.
- 6The full amended Code of Business Conduct and Ethics is available on Regeneron's investor relations website.